News

Caregivers saw improvements in patients given Daybue in Rett trials

Treatment with Daybue (trofinetide) in clinical trials helped girls and young women with Rett syndrome to communicate and use their hands better, according to interviews with caregivers of participants in two studies that tested the now-approved therapy. “Caregivers from both trials described a range of improvements, including increased…

New MeCP2 mutation found in boy with Rett syndrome

Researchers identified a new mutation in the MeCP2 gene in a Chinese boy diagnosed with Rett syndrome, a condition that rarely affects males. The boy exhibited diverse symptoms, including limited movements, breathing and sleep problems, heart and lung defects, and abnormal brain wave activity. “Our discovery of…

ID’d microRNAs may serve as Rett disease progression biomarkers

A research team has identified Rett syndrome-specific molecules that regulate gene activity, called microRNAs, that are associated with the growth of patient-derived brain cells and may serve as biomarkers for monitoring Rett progression. Using 3D organoids that mimic the brain, the team identified these microRNA fingerprints within extracellular vesicles…

Marvel’s MB204 improves social behaviors in Rett mice in study

Marvel Biosciences‘ MB204, an experimental treatment for Rett syndrome, was shown to improve social behaviors — with “durable” effects — in a mouse model of the disease. Based on these results, Marvel intends to seek orphan and/or rare disease designation from the U.S. Food and Drug Administration (FDA)…

Rett girl has severe immune reaction to high dose of NGN-401

A girl with Rett syndrome participating in a clinical trial testing gene therapy NGN-401 experienced a serious, treatment-related immune reaction. The patient, who received a high dose of NGN-401 in an ongoing Phase 1/2 trial (NCT05898620), experienced signs of systemic (body-wide) hyperinflammatory syndrome, a rare and life-threatening immune…